Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling ...
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented ...
Poster presentation: Title: Preclinical evaluation of petosemtamab, an epidermal growth factor receptor (EGFR) and leucine-rich repeat-containing G protein-coupled receptor (LGR5) bispecific antibody, ...
Actinium Pharmaceuticals (ATNM) announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer has been ...
PRINCETON, N.J. and CAMBRIDGE, Mass., Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., ...
Aumolertinib had comparable efficacy to osimertinib when treating epidermal growth factor receptor ( EGFR )-mutant non-small ...
Current treatment options for EGFR-mutant lung cancer include oral therapy combinations with chemotherapy and emerging ...
AJMC: Osimertinib is an oral drug, whereas amivantamab is an intravenous formulation. Given those differences in delivery ...
Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome ...
The global market for managing EGFR inhibitors induced skin disorders is expanding due to increased awareness and the growing use of EGFR-targeted cancer therapies. These inhibitors, crucial for ...
The authors describe an interesting approach to studying the dynamics and function of membrane proteins in different lipid environments. The important findings have theoretical and practical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback